KVACHIGH SIGNALMANAGEMENT10-K

KVAC terminated its September 2024 merger agreement and entered a new letter of intent with Medera/Novoheart in February 2026, with a critical April 10, 2026 deadline to execute a replacement merger agreement.

This represents a significant pivot in the SPAC's business combination strategy, creating execution risk as the company races against tight timelines to finalize a new deal structure. The shift to Novoheart Group, focused on pre-clinical disease modeling and drug discovery, indicates a complete change in target sector and risk profile from the previous arrangement.

Comparing 2026-03-25 vs 2025-03-07View on EDGAR →
FINANCIAL ANALYSIS

KVAC's financial position deteriorated meaningfully, with cash reserves dropping to just $11K from $55K and stockholders' equity deficit expanding to $7.0M. Share buyback activity declined substantially from $92.4M to $18.1M, while net income fell significantly from $7.4M to $1.9M. The company's liquidity position appears critically constrained as it approaches the merger deadline, with total liabilities increasing 65% to $7.0M.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
-80.4%
$92.4M→$18.1M

Buyback activity reduced 80.4% — capital being redeployed elsewhere or cash conservation underway.

Cash & Equivalents
Balance Sheet
-79.5%
$55K→$11K

Cash declined 79.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Net Income
P&L
-74.2%
$7.4M→$1.9M

Net income declined 74.2% — review whether driven by operations, interest costs, or non-recurring items.

Stockholders Equity
Balance Sheet
-67%
-$4.2M→-$7.0M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Liabilities
Balance Sheet
+65.3%
$4.3M→$7.0M

Liabilities grew 65.3% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Assets
Balance Sheet
-42.4%
$64K→$37K

Current assets declined 42.4% — monitor working capital adequacy and short-term liquidity.

Operating Cash Flow
Cash Flow
+31.4%
-$1.1M→-$784K

Operating cash flow surged 31.4% — exceptional cash generation, highest quality earnings signal.

Total Assets
Balance Sheet
-19%
$70.4M→$57.0M

Total assets contracted 19% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-03-25
PRIOR — 2025-03-07
ADDED
As of March 11, 2026, there were 5,506,521 ordinary shares issued and outstanding.
On February 26, 2026, we entered into a binding letter of intent ( LOI ) with Medera, and Novoheart Group Limited, a British Virgin Islands company and wholly owned subsidiary of Medera ( NVH ).
The LOI replaces the prior Merger Agreement dated September 3, 2024, which was terminated concurrently with execution of the LOI pursuant to a mutual release agreement entered into by the parties.
3 Under the LOI, we and NVH have agreed to use their best efforts to negotiate and execute a replacement merger agreement ( Replacement Merger Agreement ) no later than April 10, 2026.
The Replacement Merger Agreement will be based on the terms and conditions of the prior Merger Agreement, modified as necessary to reflect the parties current agreements set forth in the LOI.
The contemplated transaction involves a merger of NVH, which is principally engaged in pre-clinical human disease modeling, drug discovery, and related technologies, with and into us, with we as the surviving company and listed on Nasdaq.
The final acquisition structure and jurisdiction of the combined company will be determined following due diligence and will be optimized for tax outcomes for existing equity holders of us and NVH.
The Replacement Merger Agreement will provide that, at closing, the surviving company must have available cash, after payment of transaction expenses and net of any indebtedness of, or guaranteed by, NVH ( NVH Liabilities ), of not less than US$10,000,000.
Available liquidity will include funds from our trust account (after all redemptions), proceeds from any private investment in public equity ( PIPE ) fundraising, and NVH s balance sheet cash.
Cash expenses to be paid at closing are capped at US$700,000 for us and US$1,300,000 for NVH.
REMOVED
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
As of March 4, 2025, there were 10,820,727 ordinary shares issued and outstanding.
(OTC Pink Sheets: RAHGF), and as of July 6, 2023 (approximately six years after the consummation of the business combination), the market capitalization of RAHGF was approximately $0.33 million as a result of change of regulatory regime in the PRC regarding the peer-to-peer lending industry and CLG s subsequent transition of its business from peer-to-peer lending business to financial management, assessment and consulting services, debt collecting services, and financial guarantee services.
On October 25, 2024, we held an annual meeting of shareholders.
our shareholders approved the proposal to amend our amended and restated memorandum and articles of association to extend the date by which we have to consummate a business combination three times for nine additional months each time from October 27, 2024 to July 27, 2025 by depositing into the Trust Account $200,000 for all remaining public shares (the Extension Payment ) for each one-month extension.
As of the date of this annual report, we further extended the time to consummate our initial business combination to March 27, 2025.
As of the date of this annual report, we have issued a total of 5 promissory notes in the aggregate amount of $1,000,000 to our sponsor.
For a more detailed discussion of the uncertainties relating to business combination with a China-based company, see Risk Factors Risks Relating to Acquiring a Company with Operations in China.
Holders of Record At February 27, 2025, there were 10,820,727 of our ordinary shares held by 2 shareholders issued and outstanding.
Liquidity and Capital Resources As of December 31, 2024, we had cash of $54,548 and investments held in the Trust Account of $70,373,065.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →